Lexicon Fires Back after Sanofi Ends Up-to-$1.7B Diabetes Collaboration
Preclinical and clinical SGLT1, SGLT2, and dual SGLT1/2 inhibitors. | Download Scientific Diagram
Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care | Diabetes Technology & Therapeutics
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control | Nature Reviews Cardiology
Dual SGLT1/SGLT2 Inhibitor Phlorizin Ameliorates Non-Alcoholic Fatty L | DMSO
Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, in overweight/obese patients with type 1 diabetes: addressing unmet needs as adjunct therapy to insulin - Media Centre | EASD
Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus. - Abstract - Europe PMC
Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus. - Abstract - Europe PMC
Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials | The BMJ
SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review
Clinical Significance Of SGLT-2 | Our Biochemistry- Namrata Chhabra
Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors - Yakovleva -
SGLT2 Inhibitors – Diabetologia
Development of SGLT1 and SGLT2 inhibitors | SpringerLink
Kidney and Dialysis | Free Full-Text | The Pathophysiological Basis of Diabetic Kidney Protection by Inhibition of SGLT2 and SGLT1
Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 Inhibitor Canagliflozin with SGLT1 and SGLT2: Inhibition Kinetics, Sidedness of Action, and Transporter-Associated Incorporation Accounting for its Pharmacodynamic and Pharmacokinetic Features ...
The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus | SpringerLink
Sodium–glucose cotransporters: Functional properties and pharmaceutical potential - Sano - 2020 - Journal of Diabetes Investigation - Wiley Online Library
24-week efficacy and safety of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes (inTandem2) - Media Centre | EASD
Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives | Cardiovascular Diabetology | Full Text
IJMS | Free Full-Text | Crosstalk between Sodium–Glucose Cotransporter Inhibitors and Sodium–Hydrogen Exchanger 1 and 3 in Cardiometabolic Diseases
SGLT inhibitors: a novel target for diabetes | Pharmaceutical Patent Analyst
The Na+‐D‐glucose cotransporters SGLT1 and SGLT2 are targets for the treatment of diabetes and cancer | Semantic Scholar
SGLT inhibitors in management of diabetes - The Lancet Diabetes & Endocrinology
Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Sodium–Glucose Co-transporter-2 Inhibitors – touchENDOCRINOLOGY
